Published in Cancer on March 01, 2005
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol (2009) 2.09
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol (2015) 2.06
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology (2010) 1.53
The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol (2012) 1.51
Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol (2015) 1.16
Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology (2008) 1.05
Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev (2008) 1.00
Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology (2008) 0.99
Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev (2014) 0.98
The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate (2011) 0.95
The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev (2011) 0.95
Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men. Korean J Urol (2012) 0.92
PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit (2011) 0.90
Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One (2010) 0.90
Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men younger than 50 years of age. Asian J Androl (2010) 0.87
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? J Urol (2014) 0.85
Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev Res (Phila) (2010) 0.84
The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study. Cancer Epidemiol Biomarkers Prev (2009) 0.82
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes. J Urol (2014) 0.81
Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology (2013) 0.81
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. Br J Cancer (2011) 0.81
A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol (2012) 0.80
Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population. Am J Clin Oncol (2012) 0.80
Serum prostate specific antigen changes in cynomolgus monkeys (Macaca fascicularis) on a high sugar high fat diet. Prostate (2011) 0.78
An inverse association of body mass index and prostate-specific antigen in northwest men of China: a population-based analysis. Int J Clin Exp Med (2015) 0.77
Body mass index affects the diagnosis and progression of prostate cancer in Hispanics. Ethn Dis (2010) 0.77
The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study. J Cancer Res Clin Oncol (2013) 0.77
Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men. Diabetologia (2016) 0.76
Prostate-specific antigen rising in Iranian men in correlation with body mass index, fasting blood sugar and blood lipid profile. J Nephropathol (2016) 0.75
Does obesity modify prostate cancer detection in a European cohort? Cent European J Urol (2017) 0.75
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer Causes Control (2016) 0.75
Preliminary assessment of Neck Circumference in Benign Prostatic Hyperplasia in Patients with Metabolic Syndrome. Int Braz J Urol (2017) 0.75
Prostate-specific antigen, sexual behavior, and sexually transmitted infections in US men 40-59 years old, 2001-2004: a cross-sectional study. Infect Agent Cancer (2007) 0.75
Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels. Mol Clin Oncol (2017) 0.75
Obesity inversely correlates with prostate-specific antigen levels in a population with normal screening results of prostate cancer in northwestern China. Braz J Med Biol Res (2016) 0.75
Trends and co-trends of prostate-specific antigen and body mass index in a screened population. Urology (2011) 0.75
Has blood volume an impact on serum PSA levels? World J Urol (2009) 0.75
Impact of poor glycemic control of type 2 diabetes mellitus on serum prostate-specific antigen concentrations in men. Prostate Int (2017) 0.75
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Rethinking screening for breast cancer and prostate cancer. JAMA (2009) 7.83
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Accessing antiretroviral therapy following release from prison. JAMA (2009) 5.45
Is it time to abandon the food frequency questionnaire? Cancer Epidemiol Biomarkers Prev (2005) 4.11
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature (2006) 4.00
VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol (2004) 3.97
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol (2006) 2.56
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med (2008) 2.43
Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study. Am J Epidemiol (2003) 2.38
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol (2012) 2.28
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
A video game improves behavioral outcomes in adolescents and young adults with cancer: a randomized trial. Pediatrics (2008) 1.98
Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev (2002) 1.92
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2004) 1.91
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
A comprehensive examination of health conditions associated with obesity in older adults. Am J Prev Med (2004) 1.89
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol (2003) 1.74
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2011) 1.71
Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer (2009) 1.70
Development and evaluation of a study design typology for human research. AMIA Annu Symp Proc (2009) 1.70
Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med (2008) 1.68
Obesity and screening for breast, cervical, and colorectal cancer in women: a review. Cancer (2008) 1.67
Do the morphological characteristics of arteriovenous malformations affect the results of radiosurgery? J Neurosurg (2004) 1.67
Relationships between welfare status, health insurance status, and health and medical care among children with asthma. Am J Public Health (2002) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res (2009) 1.60
The human studies database project: federating human studies design data using the ontology of clinical research. AMIA Jt Summits Transl Sci Proc (2010) 1.58
The carbon isotope ratio of alanine in red blood cells is a new candidate biomarker of sugar-sweetened beverage intake. J Nutr (2013) 1.55
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol (2009) 1.55
Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer (2007) 1.54
Improving the performance of physiologic hot flash measures with support vector machines. Psychophysiology (2009) 1.54
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol (2013) 1.53
Breast-feeding and neuroblastoma, USA and Canada. Cancer Causes Control (2002) 1.51
Linear accelerator radiosurgery for vestibular schwannomas. J Neurosurg (2006) 1.51
Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol (2005) 1.50
Prostate-specific antigen: a misused and maligned prostate cancer biomarker. J Natl Cancer Inst (2008) 1.49
Maternal vitamin use and reduced risk of neuroblastoma. Epidemiology (2002) 1.48
Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol (2006) 1.48
Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer (2007) 1.47
Principles for the ethical analysis of clinical and translational research. Stat Med (2011) 1.47
Concern Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol (2012) 1.46
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2008) 1.46
Linear accelerator surgery for meningiomas. J Neurosurg (2005) 1.43
Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol (2006) 1.43
Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol (2008) 1.42
Use of supplements of multivitamins, vitamin C, and vitamin E in relation to mortality. Am J Epidemiol (2009) 1.42
Adherence to WCRF/AICR cancer prevention recommendations and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Is olestra consumption associated with changes in dietary intake, serum lipids, and body weight? Nutrition (2003) 1.41
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol (2013) 1.41
Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy. J Pediatr Hematol Oncol (2002) 1.40
Red blood cell delta15N: a novel biomarker of dietary eicosapentaenoic acid and docosahexaenoic acid intake. Am J Clin Nutr (2009) 1.38
Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol (2002) 1.37
Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev (2006) 1.33
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol (2011) 1.33
Assessment of a one-page questionnaire on long-term recreational physical activity. Epidemiology (2004) 1.32
Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis (2004) 1.30
Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control (2007) 1.30
Reliability and validity of 2 single-item measures of psychosocial stress. Epidemiology (2006) 1.30
Stable nitrogen and carbon isotope ratios indicate traditional and market food intake in an indigenous circumpolar population. J Nutr (2011) 1.29
Strategies for developing biostatistics resources in an academic health center. Acad Med (2013) 1.27
Anthropometrics and prostate cancer risk. Am J Epidemiol (2007) 1.25
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys (2013) 1.25
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.23
CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice. J Neurosci (2011) 1.22
Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control (2007) 1.22
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol (2003) 1.21
The infectious disease profile of Texas prison inmates. Prev Med (2004) 1.21
Development and validation of the mindful eating questionnaire. J Am Diet Assoc (2009) 1.19
Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. J Altern Complement Med (2004) 1.18
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am J Clin Nutr (2010) 1.17
Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn (2008) 1.17
Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev (2005) 1.17
Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr (2010) 1.15